name: william g. blum, m.d. - ohio state university · name: william g. blum, m.d. office address:...

William Blum, MD 6.2016

Name: WILLIAM G. BLUM, M.D. Office Address: The Ohio State University B312 Starling Loving Hall, 320 W. 10th Ave Columbus, OH 43210 Office phone: 614-293-9869 Office fax: 614-293-7526 Cell phone 614-406-4123 Email: [email protected] Date of Birth: December 16, 1970 Place of Birth: Lynn, Massachusetts Citizenship: U.S.A. Married: Kristie A. Blum, M.D. Children: Son: Jonah (12) Son: Jack (10) Son: Peter (6) Education: 1993 B.S. University of Notre Dame; Notre Dame, IN 1997 M.D. Medical College of Georgia; Augusta, GA Postdoctoral Training: 1997-1998 Intern in Internal Medicine; University of Virginia, Charlottesville, VA 1998-2000 Resident in Internal Medicine; University of Virginia, Charlottesville, VA 2000-2003 Fellow in Hematology/Oncology; Washington University, St. Louis, MO Academic Appointments: 2003- 2010 Assistant Professor of Medicine Division of Hematology/ Oncology James Cancer Hospital, The Ohio State University; Columbus, OH 2008-present Cadre Member, Alliance for Clinical Trials in Oncology (Alliance, formerly

CALGB) Leukemia Committee 2010-present Chair – OSU Comprehensive Cancer Center (CCC) Data and Safety

Monitoring Committee (DSMC) 2010-2015 Associate Professor of Medicine with Tenure Division of Hematology James Cancer Hospital, The Ohio State University, Columbus, OH 2013-2015 Section Head, Acute Myeloid Leukemia and Myelodysplastic Syndromes

(sections dissolved 2015 in favor of a general leadership council of which I am a member)

Division of Hematology The Ohio State University School of Medicine; Columbus, OH 2015-present Professor of Medicine with Tenure


Division of Hematology James Cancer Hospital, The Ohio State University, Columbus, OH Medical Licensure: 2003-present Medical License (full) Ohio National Boards: 2001 Certification in Internal Medicine 2004, 2014 Certification in Hematology 2004 Certification in Medical Oncology Awards and Honors: 1991 Summer Research Student Award, lab of Douglas Boyd, The MD Anderson

Cancer Center 1992 Summer Research Student Award, lab of David Harrison, Jackson

Laboratory; Bar Harbor, ME 1994-1995 School of Medicine Scholarship, Medical College of Georgia 1995 CD Whitaker Scholarship, Medical College of Georgia 1995 Academic Commendation letter, Medical College of Georgia 1995 Award for Excellence in Scholarship, Medical College of Georgia 1996 Alpha Omega Alpha, Medical College of Georgia 2000 Awarded Jefferson Cup for excellence in resident research, University of

Virginia 2003 Selected Participant, AACR/ASCO Workshop “Methods of Clinical Cancer

Research” 2004 Selected Participant, ASH Clinical Research Training Institute (CRTI) 2003-2009 Service Award in the College of Medicine Education Programs, The Ohio

State University 2010 Chair and invited speaker, Education session for myelodysplastic

syndromes, American Society of Hematology Annual Meeting 2011 Invited speaker, American Society of Hematology Annual Meeting Highlights

lecture series 2011-present Best Doctor’s In America 2013 Invited consultant, American Society of Hematology Consult a Colleague

Program 2014 Invited consultant, Genentech, in an Acute Myeloid Leukemia Advisory

Board (Jan 31) 2014 Invited speaker, Education session for Acute Myeloid Leukemia, American

Society of Clinical Oncology Annual Meeting (May 31) 2014 Invited Speaker, Debate Topic: Are Hypomethylating Agents the Standard of

Care for Older Adults with AML Not Candidates for Intensive Chemotherapy? Society of Hematologic Oncology (SOHO) (Sept 18)

2014 Invited Speaker, AML Therapy – State of the Art, ImmunoGen, Inc. (Nov 19) 2015 NPR Radio Interview (St. Louis Public Radio/90.7 KWMU), University of

Missouri, St. Louis. Immune based therapies/trends in AML care and research. (Jan 12)

2015 Invited Speaker, American Red Cross Platelet Event: How platelets are used to help patients. Columbus Museum of Art. (July 11)

2015 Selected Participant, Research Advisory Board (Abbvie)


2015 Selected Participant, Research Advisory Board (Boehringer Ingelheim) 2015 Selected Participant, Research Advisory Board (Immunogen) 2015 Invited Speaker, International Conference on Acute Myeloid Leukemia,

Molecular and Translational Advances in Biology and Treatment: Hypomethylating agents. Budapest, Hungary (Sept 10)

2016 Invited Speaker, Acute Leukemia Forum 2016, Newport Beach, CA. “Why the stagnation in therapy for MDS?” (Mar 2016)

2016 Invited Speaker, University of Pittsburgh. “Clinical Trials in AML” Pittsburgh, PA (April 28th)

2016 Selected Participant, Research Advisory Board (Novartis, May 21st) Professional Memberships:

American Society of Hematology Alpha Omega Alpha

American Association of Cancer Research American Society of Clinical Oncology American Society of Bone Marrow Transplantation Alliance Cooperative Group for Clinical Trials in Oncology (Cadre Member)

Contributions to National/institutional Professional Organizations National 2006, 2010, 2012 Abstract Reviewer (Category: AML: Therapy), American Society of Hematology Annual Meeting 2006 Moderator, Oral Simultaneous Session: Acute Myeloid Leukemia Therapy, American Society of Hematology Annual Meeting 2006–2012 Ad hoc member, Audit Committee, Cancer and Leukemia Group B 2010 Moderator, Oral Abstract Session: Leukemia, Myelodysplasia and

Transplantation, American Society of Clinical Oncology Annual Meeting 2010 Moderator, Oral Abstract Session: Acute Myeloid Leukemia – Therapy,

excluding Transplantation: Pediatric and Adult AML Therapy, American Society of Hematology Annual Meeting

2010 Chair, Education session for MDS, American Society of Hematology Annual

Meeting, invited speaker for same session, “How much, how often, how long: therapies for MDS”

2012 Oncology Drug Advisory Committee to the US FDA; Consideration of

Dacogen for acute myeloid leukemia. External Advisor to Eisai, Inc. FDA White Oak Campus, Silver Spring, MD

2012-2015 Review panel member, National Comprehensive Cancer Network (NCCN),

initial development of clinical practice guidelines for acute lymphoblastic leukemia

2013 External reviewer, protocol scientific review for European Organisation for

Research and Treatment of Cancer (EORTC)


2013 “Meet the Expert”, American Society of Hematology Annual Meeting 2013 2014 Invited speaker, Education session for AML, American Society of

Hematology Annual Meeting, “Novel therapies in AML: Hope or hype?” 2015-present Review panel member, National Comprehensive Cancer Network (NCCN),

clinical practice guidelines for acute myeloid leukemia Institutional 2003-2010 Member - Clinical Scientific Review Committee, OSU Comprehensive

Cancer Center (Vice Chair, 2006-2010) 2003–present Residency Interviewer, Dept. of Internal Medicine 2005–present Myeloid Working Group, Division of Hematology and Oncology 2005 Clinical Improvement Committee 2005 –2006 Practice Management Committee 2006 Member – Hematology/Oncology Fellowship Selection Committee 2006-2012, 2016 American Cancer Society Seed Grant Review Committee (OSU only) 2009-present Leader – Acute Leukemia Work Group 2010-present Chair – OSUCCC Data and Safety Monitoring Committee (DSMC) 2011 Fellowship Competency Committee 2011-2013 Licensed Healthcare Professionals Credentials Subcommittee 2011-2012, 2016 Poster Judge, OSU James Annual Scientific Meeting 2011-2013, 2016 Abstract Judge for OSU James Annual Scientific Meeting 2012 Member – Review Task Force for the Division of Clinical Trials within the

Department of Pharmacology, OSU Medical Center 2012-present OSUCCC IRP Clinical/Translational Grant Reviewer 2015, 2016 American Society of Clinical Oncology (ASCO) education book reviewer 2015 Leukemia Research Programme (UK) Grant reviewer 2015 Hematology Leadership Council, Head of Clinical Research for Division of

Hematology Editorial Service/Grant review/Other (partial list):


Editorial board member: Journal of Clinical Oncology, 2013-present (3 year term) Editorial board member: Journal of the National Comprehensive Cancer Network, 2013-present British Journal of Hematology Annals of Hematology Blood Cancer Chemotherapy and Pharmacotherapy Haematologica Scandinavian Journal of Infectious Disease American Journal of Hematology Leukemia and Lymphoma Leukemia Research Italian Association of Cancer Research, Review Committee, Grant Reviewer NCI Challenge Grants, Grant Reviewer North Carolina Biotechnology Grant Reviewer Data and Safety Monitoring Board member; Celgene, Inc. Data and Safety Monitoring Board member; Celator, Inc. New England Journal of Medicine, Journal reviewer Bone Marrow Transplant, Journal Reviewer The Lancet Hematology, Journal Reviewer Clinical Service: 2003-present Attending Physician, Ambulatory Marrow Transplant Unit Clinic Arthur G. James Cancer Hospital and The Ohio State University 2003-present Attending Physician, Blood and Marrow Transplant Program Arthur G. James Cancer Hospital and The Ohio State University 2003-present Attending Physician, Hematologic Malignancy Clinic, Arthur G. James

Cancer Hospital and The Ohio State University 2003-present Attending Physician, Acute Leukemia Service, Arthur G. James Cancer Hospital and The Ohio State University Clinical Research Focus:

Acute Myeloid Leukemia Myelodysplastic Syndromes Autologous and Allogeneic Hematopoietic Stem Cell Transplantation Other Myeloid Malignancies

Teaching (OSU): Didactic, Selected lectures

2003 Lecturer – “Myeloproliterative Disorders”, First Year Medical Students 2004 Lecturer – “Myeloproliterative Disorders”, First Year Medical Students 2005 Lecturer – “Acute Leukemia”, First Year Medical Students 2005 Lecturer – “Acute Myeloid Leukemia”, Radiation Oncology Residents and

Fellows 2007 Lecturer - “Acute Promyelocytic Leukemia”, Hematology and Oncology

Fellows 2007 Lecturer – “Acute Leukemia”, Host Defense Lecture Series


2007 Lecturer – Integrated Pathway Program (Medical Sciences 662) 2007 Lecturer – “Hematologic Malignancies in the ICU”, Pulmonary Critical Care,

fellows, residents, attending physicians 2007 Lecturer – “Retinoids in hematologic malignancies”, Retinoid Study Group 2008 Lecturer – “Acute Leukemia”, Host Defense Lecture Series 2008 Lecturer - “Acute Myeloid Leukemia: Prognosis, Treatment, and the Role of Transplantation”, Genzyme Preceptorship Presentation 2009 Lecturer – “Epigenetics and Cancer”, OSU School of Medicine

(approximately 150 1st year medical students.

2009 Lecturer – “Acute Leukemia”, Host Defense Lecture Series 2009 Lecturer – “Acute Leukemias: From Bench to Bedside”, Cancer Immunology Series (approximately 20 post-graduate Ph.D. students) 2009 Lecturer – “Non-Hodgkins Lymphomas: From Bench to Bedside”, OSU

School of Medicine, Cancer Immunology Course Series (approximately 20 post-graduate

Ph.D. students) 2009 Lecturer – “Lymphomas: How has molecular science affected patient care”,

Cancer Immunology Lecture Series 2009 Lecturer – “How to interact ethically and productively with industry in clinical

trials for cancer patients,” OSU Undergraduate College of Medicine, School of Biomedical Science (BMS 583) (approximately 15 OSU undergraduate students)

2009 Lecturer – “Diagnosis and Treatment of Acute Leukemia,” Internal Medicine Resident Lecture Series

2010 Lecturer – “Epigenetics”, Med Student Lecture 2010 Lecturer – “Acute Leukemias” Med I Host Defense Lecture Series 2010 Lecturer – “MDS” Visiting Professorship Lectures for Hematology/Oncology

Fellows. Walter Reed Army Medical Center. Washington, DC

2010 Lecturer – “Leukemia/Lymphoma,” IBGP Module 9 Cancer Biology. OSU College of Medicine

2010 Lecturer – “AML,” Hematology/Oncology Fellows Lecture 2010 Lecturer – “High Risk AML,” Hematology/Oncology Fellows Lecture 2010 Lecturer – “AML,” Hematology/Oncology Fellows Lecture 2011 Lecturer – “Epigenetics”, Med Student Lecture 2011 Lecturer – “Leukemia/Lymphoma,” IBGP Module 9 Cancer Biology. OSU

College of Medicine 2011 Lecturer – “Acute Leukemia,” Internal Medicine Residents Lecture. 2012 Lecturer – IBGP 880.02-SPTS- OSU College of Medicine 2012 Lecturer – “Acute Myeloid Leukemia,” Hematology/Oncology Fellows Lecture 2013 Lecturer – “Acute Lymphoblastic Leukemia,” Hematology/Oncology Fellows

Lecture 2014 Lecturer – “Acute Myeloid Leukemia,” Internal Medicine Residents

Student Clinical Teaching:

2003 Preceptorship III, Department of Internal Medicine 2003-present Inpatient Fellow, Resident, Student Teaching 2003-present Ambulatory Fellow, Resident, Students Teaching 2003 Inpatient and Ambulatory Teaching for Medical students 2004 Preceptorship I, Division of Hematology and Oncology 2004 Preceptorship III Physician Development, Division of Hem/ Oncology


2005 Preceptorship (Hospital Based), Department of Internal Medicine 2005 Preceptorship III, College of Medicine 2006 Preceptorship (Physical Exam), Department of Internal Medicine 2003-present Continuity Clinic Fellow/Resident Preceptor 2008 Preceptorship, Department of Internal medicine 2009 Preceptorship (Med II Hospital Based), Department of Internal Medicine 2010 Preceptorship (CAPS), 1st year medical student, Department of Internal

Medicine Academic Advising: 2008-2009 Role: Advisor Jason Chandler, Fellow. Private practice, Memphis, TN. 2010-2011 Role: Mentor Jason Mendler, Fellow. Dr. Mendler is on faculty at Univ of Rochester.

2013-present Role: Mentor Karilyn Larkin, Fellow

2013-present Role: Mentor Sumithira Vasu, junior faculty at OSU

2009-present Role: Mentor Alison Walker, junior faculty at OSU

2014-present Role: Mentor Tina Bhatnagar, junior faculty at OSU

2015-present Role: Mentor Alice Mims, junior faculty at OSU Oral Presentations, International/ National Meetings: Phase I study of low dose decitabine and valproic acid (VA) in patients with acute myeloid leukemia (AML): Gene re expression, demethylation, and clinical response. Journal of Clinical Oncology. Annual Meeting Proceedings Part I. Vol 24, No. 18S, 2006: (abst#6515) Presented at the 2006 American Society of Oncology Annual Meeting, Special Clinical Science Symposium on epigenetic therapy, Atlanta Georgia, Jun 2-5 2006. "Diagnostic testing in acute leukemia’s and other hematologic malignancies: What do I send this

for?" Transplant Nursing Conference, Bone Marrow Transplant Tandem Meeting. Keystone, Colorado. February 7-9, 2007. “AML in the older adult: disease overview and current research” Oncology Nursing Society (ONS) Congress. Las Vegas, Nevada. April 25, 2007. “Treatment of acute promyelocytic leukemia” Oncology Nursing Society (ONS) Congress. Las Vegas, Nevada. April 25, 2007.


“Epigenetic therapy in AML: Histone deacetylase inhibitors” Clinical Advances in Epigenetic Therapy Conference. Charleston, South Carolina. September 9, 2007. “Challenging cases in hematology, aggressive MDS” Network for Medical Communication and Research. Las Vegas, NV. September 29, 2007. “Role of epigenetic therapy in AML” New York Chemotherapy Foundation Symposium XXV. New York, New York. November 6-10, 2007. “Translational oncology: Pathways to future cancer therapies” Network for Oncology Communication and Research Annual Conference. Las Vegas, Nevada. March 7-8, 2008. “Tanespimycin-Bortezomib phase I trial in leukemia” Proteasome Inhibitor Combination Trials with Targeted Agents Meeting, NCI. Bethesda, Maryland. April 18, 2008. “Bortezomib as an epigenetic targeting agent” Proteasome Inhibitor Combination Trials with Targeted Agents Meeting, NCI. Bethesda, Maryland. April 19, 2008. “How to get an R21 Grant” American Society of Clinical Oncology International Meeting. Orlando, Florida. June 2008. “CALGB 10503 Update and Future Plans” CALGB Leukemia Committee Meetings. 2008-2012 (multiple lectures). “Development of a new strategy for treatment of older AML patients” CALGB Leukemia Core Committee Meeting. Chicago, Illinois. September 13, 2009. “R21 Grants, Perseverance, and Resubmission” Grant Writing Workshop I: Basic Grant Writing. ASCO Annual Meeting. Chicago, Illinois. June 2009. “R21 Grants, Perseverance, and Resubmission” Grant Writing Workshop I: Basic Grant Writing. ASCO Annual Meeting. Chicago, Illinois. June 2010. “Phase I trial of decitabine and bortezomib in AML” CTEP Early Drug Development Meeting. Bethesda, Maryland. September 27, 2010. “How Much, How Frequent, How Long? A Clinical Guide to New Therapies in MDS” Myelodysplastic Syndromes, Education Program, 2010 ASH Annual Meeting. Orlando, Florida. December 4-5, 2010. “Myelodysplastic Syndromes” 2011 Highlights of ASH in North America Meeting. Vancouver, BC, Canada. January 21, 2011. “Myelodysplastic Syndromes” 2011 Highlights of ASH in North America Meeting. New York, New York. February 4, 2011. “Acute Myeloid Leukemia in Older Adults” presentation as External Advisor to Eisai, Inc; Oncology Drug Advisory Committee to the US FDA, Consideration of Dacogen for acute myeloid leukemia. FDA White Oak Campus, Silver Spring, MD. February 9, 2012. “MDS and AML: an expert discussion panel” Medscape. Online programming for CME. Cleveland, OH. September 2012.


“Novel Therapies in AML;” Hematology Grand Rounds, MD Anderson Cancer Center. Houston, TX. April 9-10, 2013. “Misery and Joy, and Joy and Misery: Clinical Research in AML”. Invited lecture, University of North Carolina. Nov, 2013. “How I Treat: Bringing Science to Clinical Dilemmas: Acute Myeloid Leukemia. 2013 ASH Annual Meeting. New Orleans, LA. Dec, 2013 “Misery and Joy, and Joy and Misery: Clinical Research in AML”. Invited lecture, Yale University. Feb, 2014. “Novel Therapies in AML: Hope or Hype?” American Society of Clinical Oncology Annual Meeting. May 2014. “Why the stagnation in therapies for MDS?” Acute Leukemia Forum, CA. Mar 2016. Oral Presentations, Regional Meetings: Spring Relay for Life Kick off Rally 2003; YMCA – Grove City, Ohio. Featured Speaker for fundraising rally of team leaders. Relay for Life 2003; American Cancer Society – Pickerington, Ohio. Featured speaker for fundraising event. Audience 200-300 people and broadcast on live radio. “Treatment of AML” a comprehensive overview of AML pathophysiology, screening, and diagnostic procedures. Nurse practitioners, pharmacists and fellows. Columbus, Ohio. November 14, 2005. “Acute myeloid leukemia and myelodysplastic syndrome” Recognizing Blood Cancers in Family Practice, Leukemia and Lymphoma Society. Columbus, Ohio. May 13, 2006. “Myelodysplastic syndromes” Exciting new developments in hematology. The Ohio State University. Columbus, Ohio. May 26, 2006. “Epigenetic therapy in the treatment of myelodysplastic syndromes,” Cancer Center Grand Rounds, William Beaumont Cancer Center. Royal Oaks, Michigan. December 6, 2006. “Acute myeloid leukemia” Leukemia and Lymphoma Society. Columbus, Ohio. October 28, 2006. “Flavopiridol in acute leukemia” Examples of collaborative use of PK/PD cores & protocol development. The Ohio State University Pediatric Oncology Program Retreat, The Ohio State University, Columbus, Ohio. December 1, 2006. “A comprehensive overview of myelodysplastic syndrome pathophysiology, screening, and diagnostic procedures.” Nurse practitioners, pharmacists and fellows. Columbus, Ohio. March 19, 2007. “The use of hypomethylating agents in treating aggressive MDS” Akron community oncologists/Summa Health Systems practitioners, Indianapolis, IN. March 20, 2007. “Emerging therapies for MDS” Akron Community Oncologist and Practitioners. Akron, Ohio. May 15, 2007.


“AML/MDS update” Oncology and Hematology 2007: Review and Interpretation of the 2007 ASCO, ASH, AACR and other Major International Meetings, The Ohio State University. Columbus, Ohio. June 16, 2007. “Decitabine, a new therapeutic option for MDS” Community Oncologist and Practitioners. Dayton, Ohio. July 9, 2007. “Myelodysplasia” ASH Review. Columbus, Ohio. January 11, 2008. “Myelodysplastic Syndromes: An Update from ASH” Leukemia & Lymphoma Society, CCONS. Columbus, Ohio. January 30, 2008. “Advances in management of myelodysplastic syndrome” Grand Rounds, Western Kentucky Medical Center/ Commonwealth Health Corporation. Bowling Green, Kentucky. August 14, 2008. “Advances in management of myelodysplastic syndrome” Grand Rounds, Parkview Hospital. Fort Wayne, Indiana. September 15, 2008. AML/MDS and Transplantation: Genzyme Preceptorship Presentation, The Ohio State University, Columbus, Ohio. October 10, 2008. “Advances in the Management of Myelodysplastic Syndrome” Grand Rounds, Good Samaritan Hospital, Zanesville, Ohio. December 18, 2008. “Acute Leukemia” ASH Annual Conference Review, Columbus, Ohio. January 9, 2009. “Myelodysplastic Syndromes” OptumHealth Education Program. Lebanon, Ohio. March 26, 2009. “Myelodysplastic Syndromes” OptumHealth Education Program. Joliet, Illinois. April 2, 2009. “Myelodysplastic Syndromes” OptumHealth Education Program. Ohio Cancer Specialist Inc. Mansfield, Ohio. April 29, 2009. “High-risk Myelodysplastic Syndromes” OptumHealth Education Program. Columbus CCOP (approximately 30 community physicians and nurses). Columbus, Ohio. September 16, 2009. “Acute Leukemias” ASH Annual Conference Review, Columbus, Ohio. January 22, 2010. “Remissions in older AML patients treated with a novel schedule of Decitabine: miR-29b as a potential predictive marker” OSUCCC Annual Scientific Meeting. Columbus, Ohio. February 19, 2010. “Advances in the Management of High-Risk AML” Atlanta, GA. April 20, 2010. “Leukemia/Myeloma” Columbus CCOP 2010 ASCO Review. Columbus, OH. June 24, 2010. “Blood Disorders that cause cytopenias” OSU MedNet 21 CME Webcast. Columbus, OH. July 1, 2011 “Myelodysplastic syndromes: a case based review”. Charles River Oncology Group, Framingham, MA. September 2012


“Myelodysplastic syndromes: a case based review”. Lima Oncology Group, Lima, OH. September 2012 Research Support Peer reviewed funding 5 R21 CA128377-02 (PI: Blum) 05/17/2009 - 04/30/2013 NCI /(ARRA) Maintenance therapy with decitabine for acute myeloid leukemia in first remission We propose adding low dose, outpatient decitabine treatment for younger patients who remain in remission after intensive chemotherapy for AML. It is hoped that decitabine will wipe out the remnants of leukemia that may be leftover after completion of chemotherapy (called minimal residual disease) and thus help to prevent relapse of AML. Important to the success of the project are the development of new tests to predict outcomes in AML and new methods to detect minimal residual disease in patients who are in remission. We hope to more accurately predict response to treatment and assess risk of relapse. 5 U01 CA076576-14 (PI: Grever) 03/15/2003 – 02/28/2013 NCI Phase I trials of anti-cancer agents. This project uses correlative studies to evaluate clinical outcomes in the context of basic science observations. The major goal of this project is to investigate Phase I agents to obtain maximum tolerated dose and to perform clinical pharmacokinetics of these agents. Role: Co-Investigator Role: Dr. Blum participates in this project by designing and implementing clinical trials with novel agents early in clinical development. This grant provides support for the pharmacokinetic and laboratory studies proposed as part of these phase I/II clinical trials. As of 2012, Dr. Blum has 5% effort on this grant as he led the development of novel data and safety monitoring for all U01 trials at OSU and chairs the oversight of this monitoring (separate from the OSUCCC DSMC). 5 R01 CA102031-07 (PI: Marcucci) 04/01/2004 – 01/31/2013 NCI Pharmacological Modulation of Epigenetic Changes in AML Through in vivo and in vitro studies, we will study how underlying molecular defects influence response to HDAC and DNMT inhibitors in specific subgroups of AML and whether combination of these agents with other specific molecular therapeutics could enhance disease response. Role: Co-Investigator 5 P50 CA140158-03 (PI: Byrd/Bloomfield/Marcucci) 08/17/2009 – 07/31/2014 NCI/SPORE Title: Experimental Therapeutics in Leukemia Project 4 Title: Pre-Clinical and Clinical Investigation of MLL PTD Acute Myeloid Leukemia Role: Project 4 Leader LLS 7004-11 (SCOR Leader: Byrd) 10/01/2010 – 09/30/2015 Leukemia & Lymphoma Society - SCOR Title: Experimental Therapeutics in Leukemia Project 2 Title: Therapeutic Targeting miR181a in Acute Myeloid Leukemia Core C Title: Clinical Trials Core The central theme of this proposal is the pursuit of pre-clinical and clinical investigations of multi-targeted therapies for the treatment of genetically high-risk CLL and AML. Role: Project 2 Leader and Core C Director


2 RC2 CA148302-02 (PI: Croce / Marcucci) 09/30/2009 – 08/31/2012 NCI Loss of miR-29s as predictor of response to demethylating agents The goal of the project is to conduct three small clinical trials to validate that loss of miR-29 is a predictor of response to demethylating agents, such as 5-azacytidine (5-Aza) and decitabine in lung cancer, AML and the aggressive form of CLL. Role: Co-Investigator 5 U10 CA77658-14 (PI: Bloomfield) 04/16/1998 – 03/31/2015 NCI / CALGB – The Ohio State University Cancer and Leukemia Group B (CALGB) - The Ohio State University Provides institutional support for The Ohio State University’s participation in CALGB protocols. To develop novel chemotherapeutic agents of combination of agents that help develop new standards of care in oncology. Role: Collaborator 1 UM1 CA186712-01 (PI: Grever) 03/28/2014 – 02/28/2019 0.60 calendar NCI $589,011 Experimental Therapeutics of Anti-Cancer Agents with Phase I Emphasis This proposal seeks to continue hypothesis driven, disease or target specific Phase I trials of promising anticancer agents alone or in combination through the Experimental Therapeutics Program of the Clinical Trials Network (ET-CTN) of the National Cancer Institute (NCI). The ultimate goal of this proposal is the development of the most effective (rather than the most toxic) dose and schedule for further therapeutic investigation of promising new anticancer agents that will be tested in the late phase clinical trials by the National Clinical Trials Network (NCTN). Role: Co-Investigator

Completed Research Support 5 K23 CA120708-04 (PI: Blum) 08/09/2006 – 11/30/2011 NCI Experimental therapeutics in acute leukemias. The goal of the study is to develop new drugs that more effectively treat adults with relapsed AML and ALL through two clinical phase I trials that target aberrant signaling and survival pathways in leukemic cells. NCI / 1 R21 CA133879-01 (PI: Marcucci) 09/30/2009 – 02/29/2012 GTI-2040: An anti-sense strategy to reduce ribonucleotide reductase in AML The overall goal of this study is to validate an effective salvage regimen that will allow relapsed/refractory AML patients to achieve high CR/CRi rates, proceed to allogeneic stem cell transplant and/or extend survival. Role: Co-Investigator Other funding 11/2003 – 11/2004 Institutional research seed grant

PI: William Blum, M.D. Agency/Type: American Cancer Society IRG-67-003-41

06/2004 - 06/2006 Phase I study of arsenic trioxide in combination with valproic acid in MDS PI: William Blum, M.D. Agency/Type: OSU sponsored, supported by Cell Therapeutics


07/2004 - 05/2006 Pharmacokinetic supplement to NCI Study CALGB C9710: a Phase IV commitment (OSU 0438). PI: William Blum, M.D. Agency/Type: Cell Therapeutics 10/2006-present OSU 06003 – A Phase I study of lenalidomide in acute leukemias and

chronic lymphocytic leukemia. PI: William Blum, M.D. Agency/Type: OSU sponsored, supported by Celgene Role: Dr. Blum is PI of the clinical trial that this funding supports. 03/2007 – 03/2008 Decitabine maintenance therapy in acute myeloid leukemia PI: William Blum, M.D. Agency/Type: Davis Bremer Grant

Role: Dr. Blum is PI of this institutional grant to develop preliminary data for CALGB 10503, decitabine as maintenance therapy for younger patients with AML in first remission

10/2007-12/2010 OSU 07008 – A Phase I/II study of active immunotherapy with GRNVAC1, autologous mature dendritic cells transfected with mRNA encoding human

telomerase reverse transcriptase (hTERT), in patients with acute myelogenous leukemia (AML)

Co-I: William Blum, M.D. Agency/Type: Geron Corp

Role: Dr. Blum is local PI of the clinical trial that this funding supports. 11/2007 – 12/2011 OSU07095 – Phase I study of Vidaza and Velcade (bortezomib) in AML PI: William Blum, M.D. Agency/Type: OSU sponsored; supported by Celgene, Millenium Role: Dr. Blum is PI of the clinical trial that this funding supports. 04/2009 – 02/2012 An Open-label, Dose Escalation, Phase I Study of IMC-EB10 in Patients

With Relapsed or Refractory Acute Myeloid Leukemia PI: William Blum, M.D. Agency/Type: ImClone Goal: Two center phase I trial of a novel monoclonal antibody 01/2011 – present SGI-110 in Acute Myeloid Leukemia PI: William Blum, M.D. Agency/Type: Astex

Role: Dr. Blum was local PI of this multi-center trial (He subsequently reassigned PI to Dr. Walsh for mentoring).

09/2012 – present Targeting CD33 with a novel monoclonal antibody in AML; A Phase I dose

escalation trial with BI 836858 in patients with refractory or relapsed acute myeloid leukemia

PI: William Blum, M.D. Agency/Type: Boehringer-Ingelheim

Role: Dr. Blum is overall PI(and local PI) of this multi-center trial and partnered with the company to design this “first in man” clinical trial.

2014 – present Phase II study of ABT-199 in AML PI: William Blum, M.D.


Agency/Type: Abbvie Role: Dr. Blum is local PI.

2016/pending Xencor pharmaceuticals/PI. Boerhinger Ingelhemi/PI. Immunogen/PI. Bergenbios/PI. Leukemia and Lymphoma Society/PI.

Publications:

1. Blum W. Advances in non-transplant therapy for chronic myelogenous leukemia. The Fellow Reporter. 2002; 7(4), 44-48.

2. Blum W, Khoury H, Lin H-S, Vij R, Goodnough LT, Devine S, Dipersio J, Adkins D. Primary

(AL) amyloidosis patients with significant organ dysfunction tolerate autologous transplantation following conditioning with single dose (550cGy) total body irradiation alone: A feasibility study. Biology of Blood and Marrow Transplantation. 2003; 9(6):397-404.

3. Blum W, Brown R, Lin H-S, Zehnbaeur B, Khoury H, Goodnough LT, Westervelt P, Vij R,

Dipersio J, Adkins D. Low dose (550cGy), single exposure total body irradiation and cyclophosphamide: consistent, durable engraftment of related donor peripheral blood stem cells with low treatment-related organ mortality and fatal organ toxicity. Biology of Blood and Marrow Transplantation. 2002; 8:612-618.

4. Vij R, Khoury H, Brown R, Goodnough LT, Devine SM, Blum W, Adkins D, DiPersio JF.

Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation. Bone Marrow Transplant. 2003; 32 (7):703-7.

5. Chohan R, Vij R, Adkins D, Blum W, Brown R, Tomasson M, Devine S, Graubert T,

Goodnough L, DiPersio J, Khoury H. Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity. British Journal of Hematology. 2003; 123:110-113.

6. Devine S, Adkins D, Khoury H, Brown R, Vij R, Blum W, Dipersio J. Recent advances in

allogeneic stem cell transplantation. J Lab Clin Med. 2003; 141(1):7-32.

7. Vij R, DiPersio J, Venkatraman P, Trinkaus K, Goodnough LT, Brown RA, Khoury H, Devine S, Oza A, Shenoy S, Blum W, and Adkins D. Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation. Blood. 2003; 101:2067-2069.

8. Hallemeier C, Girgis M, Blum W, Brown R, Khoury H, Goodnough LT, Vij R, Devine S,

Wehde M, Postma S, Lin HS, Dipersio J, Adkins D. Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants. Biol Blood Marrow Transplant. 2004; 10(5):310-9.

9. Blum W, Mrozek K, Ruppert AS, Carroll AJ, Rao KW, Pettenati MJ, Anastasi J, Larson RA,

Bloomfield CD. Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature. Cancer. 2004; 15:101(6):1420-7.

10. Hidalgo JD, Krone R, Rich MW, Blum K, Adkins D, Fan MY, Brown R, Devine S, Graubert

T, Blum W, Tomasson M, Goodnough LT, Vij R, DiPersio J, Khoury H. Related Articles,

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15111930&query_hl=7&itool=pubmed_docsum



Links Supraventricular tachyarrhythmia’s after hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant. 2004; 34(7):615-9.

11. Hoerr AL, Gao F, Hidalgo J, Tiwari D, Blum KA, Mathews V, Adkins DR, Blum W, Devine

S, Vij R, Goodnough LT, Dipersio JF, Khoury HJ. Related articles, links effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 2004; 22(22):4561-6.

12. Girgis M, Hallemeier C, Blum W, Brown R, Lin HS, Khoury H, Goodnough LT, Vij R, Devine

S, Wehde M, Postma S, Oza A, Dipersio J, Adkins D. Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide. Blood. 2005; 105(8):3035-41.

13. Marcucci G, Stock W, Dai G, Klisovic RB, Liu, S, Klisovic MI, Blum W, Kefauver C, Sher

DA, Green M, Moran M, Maharry K, Novick S, Bloomfield CD, Zwiebel JA, Larson RA, Grever MR, Chan KK, Byrd JC. Phase 1 study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol. 2005. 20; 23(15):3404-11.

14. Farag SS, Bolwell BJ, Elder PJ, Kalaycio M, Lin T, Pohlman B, Penza S, Marcucci G, Blum

W, Sobecks R, Avalos BR, Byrd JC, Copelan E. High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia. Bone Marrow Transplant. 2005; 35(7):653-61.

15. Benson DM, O'Donnell L, Krugh D, Grady T, Blum W, Williams JD, Kennedy MS, Marcucci

G. Successful management of sudden, massive immune hemolysis following ABO-incompatible allogeneic PBSCT despite methotrexate GvHD prophylaxis. Bone Marrow Transplant. 2005; 36(12):1111-2.

16. Blum W, Bolwell BJ, Phillips G, Farag SS, Lin TS, Avalos BR, Penza SL, Marcucci G, Byrd

JC, Kalaycio ME, Sobecks RM, Pohlman B, Brown S, Elder PJ, Copelan EA. High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation. Biol Blood Marrow Transplant. 2006; 12(1):61-7.

17. Hallemeier CL, Girgis MD, Blum W, Brown RA, Khoury HJ, Devine SM, Vij R, Lin HS,

Dipersio JF, Adkins DR. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity. Conditioning Regimen of 550 cGy Total Body Irradiation and Cyclophosphamide. Biol Blood Marrow Transplant. 2006; 12(7):749-57.

18. Wei X, Dai G, Marcucci G, Liu Z, Hoyt D, Blum W, Chan KK. A specific picomolar

hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices. Pharm Res. 2006; 23(6):1251-64.

19. Benson D , Elder P, Lin T, Blum W, Penza S, Avalos B, Copelan E, Farag S. High-dose

melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma. Leuk Res. 2007; 31(8)27.



http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Wei+X%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Dai+G%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Marcucci+G%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Liu+Z%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Hoyt+D%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Blum+W%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Chan+KK%22%5BAuthor%5D


20. Cheng H, Liu Z, Blum W, Byrd J, Klisovic R, Grever MR, Marcucci G, Chan KK. Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 850(1-2):206-12.

21. Trifilio SM, Bennett CL, Yarnold PR, McKoy JM, Parada J, Mehta J, Chamilos G, Palella F,

Kennedy L, Mullane K, Tallman MS, Evens A, Scheetz MH, Blum W, Kontoyiannis DP. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007; 39(7):425-9.

22. Liu Z, Xie Z, Liu S, Blum W, Perotti D, Paschka P, Klisovic R, Byrd JC Chan KK, Marcucci

G. Characterization of In-Vitro and In-Vivo Hypomethylating Effect of Decitabine in Acute Myeloid Leukemia by a Rapid, Specific and Sensitive LC-MS/MS Method. Nucleic Acids Res. 2007; 35(5):e31.

23. Liu S, Klisovic RB, Vukosavljevic T, Yu J, Paschka P, Huynh L, Pang J, Neviani P, Liu Z,

Blum W, Chan KK, Perrotti D, Marcucci G. Targeting AML1/ETO-histone deacetylase repressor complex: A novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. J Pharmacol Exp Ther. 2007; 321(3):953-60.

24. Ali NA, O'brien JM Jr, Blum W, Byrd JC, Klisovic RB, Marcucci G, Phillips G, Marsh CB,

Lemeshow S, Grever MR. Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality. Cancer. 2007; 110(1):96-102.

25. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L,

Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol. 2007; 25(25):3884-91.

26. Hamadani M, Benson DM Jr, Blum W, Garzon R, Devine SM. Pulmonary nocardia and

aspergillus co-infection in a patient with chronic graft-versus-host disease. Transpl Infect Dis. 2008; 10(1):24-6.

27. Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic

RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, Caligiuri MA, Chan KK, Wu LC, Marcucci G. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-{kappa}B-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood. 2008; 111(4):2364-73.

28. Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O,

Godley L, Burgt JV, Van Laar E, Cullen M, Macleod AR, Besterman JM, Reid GK, Byrd JC, Marcucci G. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res. 2008; 14(8):2444-9.

29. Andritsos LA, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F, Smith LL,

Lapalombella R, May SE, Raymond CA, Wang DS, Knight RD, Ruppert AS, Lehman A, Jarjoura D, Chen CS, Byrd JC. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008; 26(15):2519-25.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17389244&query_hl=1&itool=pubmed_docsum

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17389244&query_hl=1&itool=pubmed_docsum

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Liu%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Liu%20Z%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Xie%20Z%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Pang%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Yu%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lehmann%20E%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Huynh%20L%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Vukosavljevic%20T%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Takeki%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Klisovic%20RB%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Klisovic%20RB%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Baiocchi%20RA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Blum%20W%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Porcu%20P%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Garzon%20R%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Byrd%20JC%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Perrotti%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Caligiuri%20MA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Chan%20KK%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Wu%20LC%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Marcucci%20G%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1


30. Klisovic RB, Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L, Pang J, Zwiebel JA, Devine S, Byrd JC, Grever MR, Chan K, Marcucci G. Phase I Study of GTI-2040, an antisense to ribonucleotide reductase in combination with high-dose cytarabine in patients with acute myeloid leukemia. Clin Cancer Res. 2008; 14(12):3889-3895.

31. Johnston JS, Phelps MA, Blum KA, Blum W, Grever MR, Farley KL, Dalton JT.

Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 87(1):15-21.

32. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, Byrd JC, Gribben JG.

Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008; 118(7):2427-2437.

33. Hamadani M, Hofmeister CC, Jansak B, Phillips G, Elder P, Blum W, Penza S, Lin TS,

Klisovic R, Marcucci G, Farag SS, Devine SM. Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. Biol Blood Marrow Transplant. 2008; 14(7):783-9.

34. Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, Ramanunni A, Smith

LL, Blum W, Andritsos L, Wang DS, Lehman A, Chen CS, Johnson AJ, Marcucci G, Lee RJ, Lee LJ, Tridandapani S, Muthusamy N, Byrd JC. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lympocytic leukemia cells. Blood. 2008; 112(13):5180-5189.

35. Fehniger TA, Byrd JC, Marcucci G, Abboud CN, Kefauver C, Payton JE, Vij R, Blum W.

Single agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood. 2009; 113:1002-1005.

36. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J,

Muthusamy N, Havelange V, Volinia S, Blum W, Rush LJ, Perrorri D, Andreeff M, Bloomfield CD, Byrd JC, Chan K, Wu LC, Croce CM, Marcucci G. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene re-expression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009; 113(25):6411-8.

37. Hamandani M, Benson DM Jr, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum

KA, Lin TS, Marcucci G, Devine SM. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant. 2009 May; 15(5):547-53.

38. Chen P, Liu Z, Liu S, Xie Z, Aimiuwu J, Pang J, Klisovic R, Blum W, Grever MR, Marcucci

G, Chan KK. A LC-MS/MS Method for the Analysis of Intracellular Nucleoside Triphosphate Levels. Pharm Res. 2009; 26(6):1504-15.

39. Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C, O’Donnell L, Klisovic

R, Penza S, Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2009 Nov; 15(11): 1422-30.


40. Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, Blum KA, Blum W,

Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen CS, Ford R Jr, Rader C, Muthusamy N, Johnson AJ, Byrd JC. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood. 2010 April 1; 115(13):2619-2629.

41. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V,

Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010 Apr 20; 107(16):7473-7478.

42. Blum W, Phelps MA, Klisovic RB, Rozewski DM, Ni W, Albanese KA, Rovin B, Kefauver C,

Devine SM, Lucas DM, Johnson A, Schaaf LJ, Byrd JC, Marcucci G, Grever MR. Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Haematologica. 2010 Jul; 95(7):1098-105.

43. Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA, Garzon R, Walker A,

Chandler JC, Whitman SP, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd JC. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol. 2010 Nov 20; 28(33): 4919-25.

44. Blum W, How much? How frequent? How long? A Clinical guide to new therapies in

myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2010; 2010: 314-21.

45. Schroeder MA, Blum W. Evidence-based mini-review: Should patients over the age of 60

with INT-2 or high-risk myelodysplastic syndrome undergo allogeneic stem cell transplantation prior to progression to acute myelogenous leukemia? Hematology Am Soc Hematol Educ Program. 2010; 2010: 322-4.

46. Mendler J, Blum W. Myelodysplastic Syndrome: Methylation is All The Rage. ASH News

Daily 2010. 2010

47. Mendler J, Blum W. Life After Transplant: Is It Worth the Cost? ASH News Daily 2010. 2010

48. Rodriguez B, Tam HH, Frankhouser D, Trimarchi M, Murphy M, Kuo C, Parikh D, Ball B,

Schwind S, Curfman J, Blum W, Marcucci G, Yan P, Bundschuh R. A Scalable, Flexible Workflow for MethylCap-Seq Data Analysis. IEEE Int Workshop Genomic Signal Process Stat. 2011:1-4.

49. Blum W. Hypomethylating agents in myelodysplastic syndromes. Clin Adv Hematol Oncol.

2011 Feb; 9 (2):13, 126-8

50. Hamanadni M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM Jr, Blum W, Devine SM. Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. Hematol Oncol. 2011 Feb 28. doi: 10.1002/hon.985.

http://www.ncbi.nlm.nih.gov/pubmed/22484542



51. Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. TET2 mutations improve the New European LeukemiaNet risk classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol. 2011 Apr 1; 29(10): 1373-81. Epub 2011 Feb 22.

52. Troeger A, Johnson AJ, Wood J, Blum W, Andritsos LA, Byrd JC, and Williams DA. RhoH

is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans. Blood. 2012 Apr 3.

53. Blum W, Schwind S, Tarighat SS, Geyer S, Eisfeld AK, Whitman S, Walker A, Klisovic R, Byrd JC, Santhanam R, Wang H, Curfman JP, Devine SM, Jacob S, Garr C, Kefauver C, Perrotti D, Chan KK, Bloomfield CD, Caligiuri MA, Grever MR, Garzon R, Marcucci G. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood. 2012 May 7. [Epub ahead of print]

54. Aimiuwu J, Wang H, Chen P, Xie Z, Wang J, Liu S, Klisovic R, Mims A, Blum W, Marcucci

G, Chan KK. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood. 2012 May 31;119(22):5229-38. Epub 2012 Apr 19.

55. Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, Klisovic

R, Blum W, Caligiuri M, Croce CM, Marcucci G, Garzon R. Pre-clinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 2012 Jun 7. [Epub ahead of print]

56. Alvarnas JC, Brown PA, Aoun P, Ballen KK, Bellam N, Blum W, Boyer MW, Carraway HE,

Coccia PF, Coutre SE, Cultrera J, Damon LE, Deangelo DJ, Douer D, Frangoul H, Frankfurt O, Goorha S, Millenson MM, O’Brien S, Petersdorf SH, Rao AV, Terezakis S, Uy G, Wetzler M, Zelenetz AD, Naganuma M, Gregory KM. Acute Lymphoblastic Leukemia. Journal of the National Comprehensive Cancer Network. 2012 July 1;10(7):858-914

57. Yan P, Frankhouser D, Murphy M, Tam HH, Rodriguez B, Curfman J, Trimarchi M, Geyer

S, Wu YZ, Whitman SP, Metzeler K, Walker A, Klisovic R, Jacob S, Grever MR, Byrd JC, Bloomfield CD, Garzon R, Blum W, Caligiuri MA, Bundschuh R, Marcucci G. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood. 2012 Jul 11 [Epub ahead of print]

58. Hickey CJ, Schwind s, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ,

Alachkar H, Maharry K, Nicolet D, Mrózek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LD, Xi Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, and Marcucci G. Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein upregulates expression of the anti-leukemic microRNA-181a in acute myeloid leukemia. Blood. 2013 Jan 3; 121 (1) 159-69

59. Bernot KM, Siebenaler RF, Whitman SP, Zorko NA, Marcucci GG, Santhanam R, Ahmed

EH, Ngangana M, McConnell KK, Nemer JS, Brook DL, Kulp SK, Chen CS, Frankhouser D, Yan P, Bundschuh R, Zhang X, Dorrance AM, Dickerson KE, Jarjoura D, Blum W, Marcucci G, Caligiuri MA. Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML. Leukemia. 2013 May 10. doi: 10.1038/leu.2013.147. [Epub ahead of print]








60. Phillips CL, Davies SM, McMasters R, Absalon M, O'Brien M, Mo J, Broun R, Moscow JA, Smolarek T, Garzon R, Blum W, Schwind S, Marcucci G, Perentesis JP. Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults. Br J Haematol. 2013 May;161(3):406-10. doi: 10.1111/bjh.12268. Epub 2013 Feb 23.

61. Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Kefauver C, Binkley P, Byrd JC,

Grever MR, Garzon R, Phelps MA, Marcucci G, Blum KA, Blum W. Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2013 Jan 24. [Epub ahead of print]

62. Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Saradhi UV, Liu Z, Schwind S, Mims A, Byrd JC, Grever MR, Villalona-Calero MA, Klisovic R, Walker A, Garzon R, Blum W, Chan KK, Marcucci G. In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia. AAPS J. 2013 Jan;15(1):242-9. doi: 10.1208/s12248-012-9427-5. Epub 2012 Nov 22

63. Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen CS, James Lee L, Jacob S, Mrózek K, Bloomfield CD, Blum W, Garzon R, Schwind S, Marcucci G. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia. 2013 Apr;27(4):871-8. doi: 10.1038/leu.2012.342. Epub 2012 Nov 26.

64. Rodriguez BA, Frankhouser D, Murphy M, Trimarchi M, Tam HH, Curfman J, Huang R,

Chan MW, Lai HC, Parikh D, Ball B, Schwind S, Blum W, Marcucci G, Yan P, Bundschuh R. Methods for high-throughput MethylCap-Seq data analysis. BMC Genomics. 2012;13 Suppl 6:S14. doi: 10.1186/1471-2164-13-S6-S14. Epub 2012 Oct 26.

65. Schwind S, Edwards CG, Nicolet D, Mrózek K, Maharry K, Wu YZ, Paschka P, Eisfeld AK,

Hoellerbauer P, Becker H, Metzeler KH, Curfman J, Kohlschmidt J, Prior TW, Kolitz JE, Blum W, Pettenati MJ, Dal Cin P, Carroll AJ, Caligiuri MA, Larson RA, Volinia S, Marcucci G, Bloomfield CD; Alliance for Clinical Trials in Oncology. inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. Blood. 2013 Jan 10;121(2):385-91. doi: 10.1182/blood-2012-07-442772. Epub 2012 Nov 16.

66. Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, Kolitz JE,

Powell BL, Voorhees P, Wang ES, Blum W, Stone RM, Marcucci G, Bloomfield CD, Moser B, Larson RA. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2013 Mar 1;31(7):923-9. doi: 10.1200/JCO.2012.45.2177. Epub 2012 Nov 5.

67. Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, Lee RJ, Garzon R, Muthusamy N, Lee LJ, Marcucci G.Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res. 2013 May 1;19(9):2355-67. doi: 10.1158/1078-0432.CCR-12-3191. Epub 2013 Mar 14.
























68. Walker AR, Klisovic RB, Garzon R, Schaaf LJ, Humphries K, Devine SM, Byrd JC, Grever MR, Marcucci G, Blum W. Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2013 Aug 16 (epub ahead of print).

69. Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Kefauver C, Binkley P, Byrd JC, Grever MR, Garzon R, Phelps MA, Marcucci G, Blum KA, Blum W. Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2013 Sept;54(9):1996-2002. doi: 10.3109/10428194.2012.760733. Epub 2013 Jan 24

70. Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Saradhi UV, Liu Z, Schwind S, Mims A, Byrd JC, Grever MR, Villalona-Calero MA, Klisovic R, Walker A, Garzon R, Blum W, Chan KK, Marcucci G. In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia..AAPS J. 2013 Jan;15(1):242-9. doi: 10.1208/s12248-012-9427-5. Epub 2012 Nov 22.

71. Bernot KM, Nemer JS, Santhanam R, Liu S, Zorko NA, Whitman SP, Dickerson KE, Zhang M, Yang X, McConnell KK, Ahmed EH, Muñoz MR, Siebenaler RF, Marcucci GG, Mundy-Bosse BL, Brook DL, Garman S, Dorrance AM, Zhang X, Zhang J, Lee RJ, Blum W, Caligiuri MA, Marcucci G. Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease. Blood. 2013 Nov 28;122(23):3778-83. doi: 10.1182/blood-2013-06-507426. Epub 2013 Oct 1.

72. Wetzler M, Watson D, Stock W, Koval G, Mulkey FA, Hoke EE, McCarty JM, Blum W, Powell BL, Marcucci G, Bloomfield CD, Linker CA, Larson RA. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica. 2014 Jan;99(1):111-5. doi: 10.3324/haematol.2013.085811. Epub 2013 Sep 27.

73. Klisovic RB, Blum W, Liu Z, Xie Z, Kefauver C, Huynh L, Zwiebel JA, Devine SM, Byrd JC, Grever MR, Chan KK, Marcucci G. Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2013 Nov 1. [Epub ahead of print]

74. Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest. 2013 Oct 1;123(10):4144-57. doi: 10.1172/JCI68951. Epub 2013 Sep 3

75. Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Tarighat SS, Volinia S, Whitman SP, Paschka P, Hoellerbauer P, Wu YZ, Han L, Bolon BN, Blum W, Mrózek K, Carroll AJ, Perrotti D, Andreeff M, Caligiuri MA, Konopleva M, Garzon R, Bloomfield CD, Marcucci G. SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. J Clin Invest. 2014 Mar 3. pii: 70921. doi: 10.1172/JCI70921























76. Blum W. Cancer immunology, success without sequencing. Journal of the National

Comprehensive Cancer Network. 2014 Mar 1;12(3):443-5.

77. Larkin, K and Blum W. Novel therapies in AML: reason for hope, or just hype? ASCO Education Book 2014 (accepted for publication)

78. Meir Wetzler, Dorothy Watson, Wendy Stock, Gregory Koval, Flora A. Mulkey, Eva E. Hoke, John M. McCarty, Blum W, Bayard L. Powell, Guido Marcucci, Clara D. Bloomfield, Charles A. Linker, Richard A. Larson. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: Results of CALGB study 10001 (alliance). 2014 PMID: 24077846.

79. Rebecca B. Klisovic, Blum, W, Zhongfa Liu, Zhiliang Xie, Cheryl Kefauver, Lenguyen Huynh, James A. Zwiebel, Steven M. Devine, John C. Byrd, Michael R. Grever, Kenneth K. Chan, Guido Marcucci. Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia. Leukemia and Lymphoma. 2014;55(6):1332-1336.

80. Alison R. Walker, Rebecca B. Klisovic, Ramiro Garzon, Larry J. Schaaf, Kristina Humphries, Steven M. Devine, John C. Byrd, Michael R. Grever, Guido Marcucci, Blum W. Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma. 2014;55(6):1304-1308.

81. S M Jaglowski, A S Ruppert, C C Hofmeister, P Elder, Blum W, R Klisovic, S Vasu, S

Penza, Y A Efebera, D M Benson Jr, S M Devine, L A Andritsos. The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma. Bone Marrow Transplantation. July 28,2014.

82. Jan H. Beumer, Kouros Owzar, Lionel D. Lewis, Chen Jiang, Julianne L. Holleran, Susan

M. Christner, Blum W, Steven Devine, Jonathan E. Kolitz, Charles Linker, Ravi Vij, Edwin P. Alyea, Richard A. Larson, Mark J. Ratain, Merrill J. Egorin. Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemotherapy and Pharmacology. 2014.

83. Salem G, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos L, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera YA.Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. Leuk Lymphoma. 2014 Nov 20:1-8. [Epub ahead of print] PMID: 25166008

84. Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrózek K, Bucci D, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Moore JO, Eisfeld AK, Blachly JS, Blum W, Caligiuri MA, Stone RM, Marcucci G, Croce CM, Byrd JC, Bloomfield CD. Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2014 Dec 15.

85. Ranganathan P, Yu X, Santhanam R, Hofstetter J, Walker A, Walsh K, Bhatnagar B, Klisovic R, Vasu S, Phelps MA, Devine S, Shacham S, Kauffman M, Marcucci G, Blum W, Garzon R. Decitabine priming enhances the anti-leukemic effects of exportin 1 (XPO1)



selective inhibitor selinexor in acute myeloid leukemia. Blood. 2015 Apr; 12517). DOI 10. 1182/blood-2014-10-607648. PMCID: PMC4408293

86. Roddy JV, Haverkos BM, McBride A, Leininger KM, Jaglowski S, Penza S, Klisovic R, Blum W, Vasu S, Hofmeister CC, Benson DM, Andritsos LA, Devine SM, Efebera YA. Tocilizumab for steroid refractory acute graft-versus-host disease. Leuk Lymphoma. 2015 Jul 3:1-5. [Epub ahead of print] PMID: 26140610

87. Efebera YA, Geyer S, Andritsos L, Vasu S, Jaglowski S, Bingman A, Blum W, Klisovic R, Hofmeister CC, Benson DM, Penza S, Elder P, Cortright K, Kitzler R, Coombes K, O'Donnell L, Daneault B, Bradbury H, Zhang J, Chen X, Garman S, Ranganathan P, Yu X, Hofstetter J, Yu J, Garzon R, Scrape SR, Lozanski G, Devine SM. Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT). Biol Blood Marrow Transplant. 2016 Jan;22(1):71-9. doi: 10.1016/j.bbmt.2015.07.034. Epub 2015 Aug 6. PMID: 26256940

88. Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, Champlin RE, Chen YB, Vij R, Slack J, Soiffer RJ, Larson RA, Shea TC, Hars V, Sibley AB, Giralt S, Carter S, Horowitz MM, Linker C, Alyea EP. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015 Dec 10;33(35):4167-75. doi: 10.1200/JCO.2015.62.7273. Epub 2015 Nov 2. PMID: 26527780

89. Castillo JJ, Mulkey F, Geyer S, Kolitz JE, Blum W, Powell BL, George SL, Larson RA, Stone RM. Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials. Am J Hematol. 2016 Feb;91(2):199-204. doi: 10.1002/ajh.24230. Epub 2015 Nov 26. PMID: 26526191

90. Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, Donnell LO, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM. Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant. 2015 Dec 29. pii: S1083-8791(15)01910-2. doi: 10.1016/j.bbmt.2015.12.015. [Epub ahead of print]. PMID: 26743340

91. Walker AR, Wang H, Walsh K, Bhatnagar B, Vasu S, Garzon R, Canning R, Geyer S, Wu YZ, Devine SM, Klisovic R, Blum W, Marcucci G. Midostaurin, bortezomib and MEC in relapsed/ refractory acute myeloid leukemia. Leuk Lymphoma. 2016 Jan 19:1-9. [Epub ahead of print]. PMID: 26784138

92. Vasu S, He S, Cheney C, Gopalakrishnan B, Mani R, Lozanski G, Mo X, Groh V, Whitman SP, Konopitzky R, Kössl C, Bucci D, Lucas DM, Yu J, Caligiuri MA, Blum W, Adam PJ, Borges E, Rueter B, Heider KH, Marcucci G, Muthusamy N. Decitabine enhances Fc engineered anti-CD33 mAb mediated natural killer antibody dependent cellular cytotoxicity against AML blasts. Blood. 2016 Mar 24. pii: blood-2015-11-680546. [Epub ahead of print]

93. Park IK, Mundy-Bosse B, Whitman SP, Zhang X, Warner SL, Bearss DJ, Blum W, Marcucci G, Caligiuri MA.Receptor tyrosine kinase Axl is required for resistance of leukemic






cells to FLT3-targeted therapy in acute myeloid leukemia. Leukemia. 2015 Dec;29(12):2382-9. doi: 10.1038/leu.2015.147. Epub 2015 Jun 19.

Abstracts:

1. Khoury H, Adkins D, Pence H, Shenoy S, Blum W, Westervelt P, Vij R, Brown R, Goodnough LT, DiPersio J. Hydroxychloroquine for prevention of acute GVHD in unrelated donor (URD) transplantation: effect on chronic GVHD and long-term survival. Blood 2001 abstract #5246

2. Omotoso O, Khoury H, Adkins D, Blum W, Iregui M, Westervelt P, Vij R, Brown R,

Goodnough LT, DiPersio J. Outcomes of stem cell transplant recipients requiring mechanical ventilation and cared for in the bone marrow transplant unit. Blood 2001 abstract #5167

3. Brown R, Adkins D, Khoury H, Westervelt P, Goodnough LT, Vij R, Blum W, DiPersio J.

Mobilization of allogeneic PBSC with GM-CSF instead of G-CSF is associated with a reduced risk of acute Graft-Verses-Host Disease (GVHD). Blood 2001 abstract #3074

4. Blum W, Brown R, Khoury H, Lin HS, Vij R, Oza Y, Schultz P, Rearden T, Willis R,

Naughton M, Goodnough LT, Westervelt P, DiPersio J, Adkins D. Primary amyloidosis (AL) patients with significant organ dysfunction treated with conventional chemotherapy followed by single-dose Total Body Irradiation (TBI) and tolerance and efficacy. Blood 2001 abstract #2862

5. Girgis M, Hallemeier C, Brown R, Khoury H, Zehnbauer B, Goodnough LT, Westervelt P,

Vij R, Blum W, Lin H-S, DiPersio J, Adkins D. Low-dose (550 cGy), single exposure Total Body Irradiation (TBI) and Cyclophosphamide as conditioning for Unrelated Donor (URD) Bone Marrow Transplantation (BMT) results in reduced Non-Relapse Mortality (NRM) in comparison to standard TBI-based regimens. Blood 2001 abstract #2810

6. Shenoy S, Hayashi R, Goodnough LT, Khoury H, Brown R, Vij R, Blum W, DiPersio J,

Adkins D. Sustained improvement in post-transplant NK cell function following donor derived G-CSF mobilized granulocyte transfusion in recipients of allogeneic peripheral blood Stem Cell Transplants (SCT). Blood 2001 abstract #240

7. Blum W, Hallemeier C, Vij R, Shenoy S, Goodnough LT, Brown R, Khoury H, Westervelt P,

DiPersio J, Adkins D. Improved survival in allogeneic peripheral blood stem cell (PBSC) transplant patients who received prophylactic granulocyte transfusions from HLA-matched donors: long-term follow-up. Blood 2001 abstract #235

8. Girgis M, Brown R, Khoury H, Hallemeier C, Zehnbauer B, Goodnough LT, Westervelt P,

Vij R, Blum W, Lin HS, DiPersio J, Adkins D. Low-dose (550 cGy) single exposure Total Body Irradiation (TBI) and cyclophosphamide as conditioning for Unrelated Donor (URD) Bone Marrow Transplant (BMT) results in consistent donor cell engraftment without fatal Regimen-Related Toxicity (RROT). Blood 2001 abstract #1999

9. Girgis M, Hallemeier C, Blum W, Brown R, Lin HS, Khoury H, Goodnough LT, Vij R, Devine

S, Wehde M, Postma S, DiPersio J, Adkins D. Low-Dose (550 CGY), Single-Exposure Total Body Irradiation (TBI) with Cyclophosphamide as Conditioning for 99 Patients Undergoing Unrelated Donor (URD) Bone Marrow Transplantation (BMT) Results in a Graft Failure Rate (7.1%). Comparable to That Observed with Standard TBI-Based Regimens. Blood 2002 abstract # 2441



10. Devine SM, Adkins DR, Khoury H, ViJ R, Goodnough LT, Graubert T, Tomasson M, Blum

W, DiPersio JF, Brown RA. Mobilization of donors with GM-CFS plus or GM-CSF alone results in significantly different graft composition compared to G-CFS alone. Blood 2002 abstract # 3259

11. Devine SM, Adkins DR, Khoury H, Vij R, Goodnough LT, Graubert T, Tomasson M, Blum

W, DiPersio JF, Brown RA. Impact of GM-CFS mobilization on the composition of donor allografts and the risk of acute GVHD following HLA-matched hematopoietic cell transplantation. Blood 2002 abstract #655

12. Blum W, Girgis M, Hallemeier C, Vij R, Lin HS, Khoury H, Goodnough LT, Devine S,

DiPersio J, Brown R, Adkins D. Outcomes for patients with non-Hodgkin’s lymphoma following donor transplantation using low dose, single exposure total body irradiation and cyclophosphamide conditioning: A single institution experience. Blood 2002 abstract #1653

13. Hallemeier C, Girgis M, Blum W, Brown R, Lin HS, Khoury H, Goodnough LT, Vij R, Devine

SM, Wehde M, Postma S, DiPersio J, Adkins D. Low-dose (550 cGy), single exposure total body irradiation (TBI) and cyclosphosphamide as conditioning for unrelated donor (URD) bone marrow transplantation (BMT) for patients with acute myelogenous leukemia (AML) in complete remission (CR) results in reduced non-relapse mortality (NRM) and improved survival in comparison to standard TBI regimens. Blood 2002 abstract #2505

14. Copelan E, Penza S, Lin T, Farag S, Blum W, Elder P, Ezzone S, Avalos B. Matched

unrelated transplantation in older individuals. Blood 2003 abstract #5647

15. Copelan, E, Penza S, Lin T, Blum W, Elder P, Ezzone S, Avalos B, Farag S. Results of allogeneic transplantation using fully myeloablative preparation in patients who are candidates for reduced intensity regimens. Blood 2003 abstract #1736

16. Blum W, Bolwell B, Farag S, Lin T, Avalos B, Penza S, Marcucci G, Byrd J, Kalaycio M,

Sobecks R, Pohlman B, Brown S, Elder P, Copelan E. Only those refractory AML patients with low disease burden can achieve prolonged leukemia-free survival with conventional unrelated donor transplantation. Blood 2003 abstract #1776

17. Hallemeier C, Girgis M, Khoury H, Devine SM, Blum W, Vij R, Lin H, DiPersio J, Adkins D.

Similar outcomes in patients 50 years old and patients < 50 years old undergoing unrelated donor bone marrow transplantation following reduced intensity conditioning with single exposure (550cGy) total body irradiation and cyclophosphamide. Blood 2003 abstract #1764

18. Hallemeier C, Girgis M, Khoury H, Devine SM, Blum W, Vij R, Lin H, DiPersio J, Adkins D.

Allogeneic stem cell transplantation of 45 patients with myelodysplastic syndrome conditioned with an intermediate-intensity regimen of single exposure 550 cGy total body irradiation and cyclophosphamide. Blood 2003 abstract #1702

19. Copelan E, Penza S, Lin T, Blum W, Farag S, Elder P, Avalos B. Association between

regimen related toxicity and acute-graft-versus-host disease. Blood 2003 abstract # 5017

20. Marcucci G, Stock W, Dai G, Liu S, Klisovic R, Klisovic M, Sher D, Huynh L, Frankel S, Blum W, Larson R, Grever M, Byrd J, Chan K. Intracellular levels of oblimersen sodium


and target downregulation correlates to clinical activity of bcl-2 antisense in acute myeloid leukemia (AML). Blood 2004 abstract #1170

21. Benson D, Elder P, Lin T, Blum W, Penza S, Avalos B, Byrd J, Copelan E, Farag, S.

Single institution experience with two high-dose chemotherapy (HDC) conditioning regimens prior to autologous stem cell transplant (ASCT) for multiple myeloma (MM). Blood 2004 abstract #5214

22. Blum W, Penza S, Farag S, Avalos B, Marcucci G, Lin T, Byrd J, Elder P, Copelan E.

Incidence of extramedullary relapse of acute myeloid leukemia following transplantation with busulfan-based conditioning regimens. Blood 2004 abstract #5123

23. Blum W, Blum K, Kefauver C, Moran M, Chan K, Byrd J, Cataland S, Grever M, Marcucci

G. Decitabine-induced differentiation syndrome in a patient with acute myeloid leukemia: A case report. Blood 2004 abstract #4528

24. Blum W, Mrozek K, Ruppert AS, Carroll AJ, Rai KW, Pettenati MJ, Vardiman JW, Larson

RA, Bloomfield CD, CALGB. Early allogeneic transplantation for adults with de novo acute myeloid leukemia presenting with t (6; 11) (q27; q23): Results from CALGB 8461. JCO 2004 abstract #6543

25. Klisovic R, Blum W, Wei X, Liu S, Kefauver C, Huynh L, Zwiebel JA, Byrd JC, Grever M,

Marcucci GA. phase I study of GTI-2040, an antisense to ribonucleotide reductase (RNR) in combination with high-dose cytarabine (HiDAC) in relapsed or refractory acute myeloid leukemia (AML): pharmacokinetics (PK), pharmacodynamic (PD) and clinical results. Blood 2005 abstract # 2790

26. Blum W, Klisovic R, Liu S, Byrd JC, Liu Z, Chan KK, Kefauver C, Huynh L, Grever M,

Marcucci G. Phase I study of low dose decitabine in patients with acute myeloid leukemia (AML): Pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity. Blood 2005 abstract #1861

27. Blum W, Mrózek K, Maharry K, Raimondi SC, Carroll AJ, Larson RA, Rowley JD,

Bloomfield CD. Comparison of de novo vs. therapy-related acute leukemia (AL) and myelodysplastic syndromes (MDS) in adults with balanced chromosome aberrations of 11q23. JCO 2005 abstract #6549

28. Klisovic R, Blum W, Hackanson B, Kefauver C, Liu S., Liu Z, Chan KK, Plass C., Grever

MR,. Byrd JC, Marcucci G. Updated results of a phase I study of low dose decitabine and valproic acid (VA) in patients with acute myeloid leukemia (AML): Gene re expression, demethylation, and clinical response. Journal of Clinical Oncology. JCO 2006 abstract #6515

29. Marcucci G, Klisovic R, Wei W, Liu S, Paschka P, Huynh L., Zwiebel J. A., Byrd JC, M. R.

Grever, K. Chan, Blum W. A phase I study of GTI-2040 (G), an antisense to ribonucleotide reductase (RNR), in combination with high-dose AraC (HiDAC) in acute myeloid leukemia. JCO 2006 abstract # 6561

30. Blum W, Klisovic RB, Kefauver C, Johnson A, Phelps M, Dalton JT, Lucas D, Colevas AD,

Grever MR, Marcucci G, Byrd JC. Phase I study of a novel, pharmacokinetically derived schedule of flavopiridol in acute leukemia’s: Clinical efficacy including hyperacute tumor lysis, pharmacokinetics, and pharmacodynamics. JCO 2006 abstract #6568


31. Ali NA, O'Brien JM, Blum W, Klisovic RB, Marcucci G, Phillips G, Marsh CB, Lemeshow S, Byrd, John C., Grever, Michael R. Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality. Blood 2006 abstract #5515

32. Blum W, Klisovic RB, Kefauver C, Johnson A, Phelps M, Dalton JT, Lucas , Huynh, L, Liu

S, Grever MR, Colevas AD, Marcucci G, Byrd JC. Updated Results of a Phase I Study of Flavopiridol in Acute Leukemia’s Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD). Blood 2006 abstract #4578

33. Blum W, Marcucci G, Devine H, Klisovic R. Imatinib Mesylate-Induced Complete

Cytogenetic Response in Acute Myeloid Leukemia with t(5;12)(q33;p13). Blood 2006 abstract # 4414

34. Liu S, Pang J, Yu J, Liu Z, Huynh L, Kearney J, Paschka P, Klisovic R, Baiocchi R, Blum

W, Perrotti D, Marcucci G. Bortezomib-Induced down-regulation of KIT is mediated by inhibition of Sp1 and NF-kB in AML1/ETO-Positive Cells. Blood 2006 abstract #4211

35. G. Marcucci, B. Moser W. Blum W. Stock, M. Wetzler, J. E. Kolitz, M. Thakuri, T. Carter, R.

K. Stuart, R. A. Larson. A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old. Myelodysplasia and Transplantation Session, JCO 2007 abstract #7012

36. Andritsos A, Johnson AJ, Blum W, Kefauver C, Awan F, Smith L, Lapalombella R, Wang D,

Knight R, Chen C, Byrd JC. Unacceptable toxicity of Lenalidomide when administered to CLL patients at higher doses. Blood 2007 abstract #4727

37. Garzon R, Liu S, Fabbri M, Liu Z, Pang J, Muthusamy N, Blum W, Chan K, Byrd JC, Croce

C, Marcucci G. MicroRNA (miRNA)-29b Targets DNMT3A and B and induces re-expression of the hypermethylated ESR1 and p15 Genes in Acute Myeloid Leukemia (AML). Blood 2007 abstract #718

38. Wetzler M, Stock W, Donohue K, Owzar K, Sher D, Hoke E, McCarty J, Blum W, Powell B,

Bloomfield C, Linker C, Larson R. Autologous Stem Cell Transplantation (SCT) following sequential chemotherapy and Imatinib for adults with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph + ALL) – CALGB study 10001. Blood 2007 abstract #2869

39. Blum W, Andritsos L, Johnson AJ, Klisovic R, Kefauver C, Devine S, Marcucci G, Byrd JC.

Preliminary results of a phase I trial with dose escalated lenalidomide (L) in separate cohorts of relapsed acute leukemia (AL) or chronic lymphocytic leukemia (CLL): evidence of activity in acute myeloid leukemia (AML) and toxicity in CLL at starting dos. JCO 2008 abstract #7075

40. Blum W, Klisovic R, Liu S, Garzon R, Kefauver C, Liu Z, Mickle J, Devine H, Devine S,

Grever M, Chan K, Villalona-Calero M, Byrd JC, Marcucci G. Preliminary results of a Phase II study of low dose Decitabine as a single agent in older patients (age > 60) with previously untreated Acute Myeloid Leukemia (AML). Blood 2008 abstract #2957

41. Hamandani M, Blum W, Benson D, Blum K, Porcu P, Elder P, Krugh D, Bechtel T,

Andritsos L, Garzon R, Penza S, Lin T, Devine S. Assessment of Rabbit Antithymocyte Globulin (rATG) dose-intensity in patients with hematological malignancies undergoing


Allogeneic Stem Cell Transplantation (ASCT) following Reduced Intensity Conditioning (RIC) with Fludarabine, Busulfan and rATG (FBA). Blood abstract #4405

42. Hamadani M, Blum KA, Elder P, Lin TS, Porcu P, Hofmeister C, Blum W, Marcucci G,

Benson D, Devine S. Allogeneic Stem Cell Transplantation for patients with chemo-refractory or progressive aggressive Non-Hodgkin’s Lymphomas. Blood 2008 abstract #3265

43. Benson D, Andritsos L, Hamadani M, Lin T, Flynn J, Jones JA, Blum W, Elder P, Lozanski

G, Byrd JC, Devine S. Natural Killer Cell Immune Reconstruction predicts outcomes for patients with Chronic Lymphocytic Leukemia undergoing Allogeneic Stem Cell Transplantation. Blood 2008 abstract #3300

44. Andritsos L, Hamadani M, Heerema N, Benson D, Hofmeister C, Blum W, Flynn J, Jones

JA, Elder P, Lin TS, Lozanski G, Byrd JC, Devine S. Attainment of minimal residual disease negative state is crucial for successful outcome of reduced intensity conditioning Allogeneic stem cell transplantation in advanced Chronic Lymphocytic Leukemia (CLL). Blood 2008 abstract #2170

45. Blum W, Klisovic R, Liu S, Kefauver C, Grever MR, Schaaf L, Chan K, Byrd JC, Villalona-

Calero M, Marcucci G. Efficacy of a novel schedule of decitabine in previously untreated AML, age 60 or older. JCO 2009 abstract # 7010

46. Aimiuwu J, Chen P, Xie Z, Liu Z, Liu S, Klisovic R, Blum W, Marcucci G, Chan KK.

Development and characterization of 5-Azacytidine resistance in human cancer cell lines. Abstract in American Association of Pharmaceutical Scientists (AAPS) Nov 2009

47. Blum W, Klisovic RB, Walker A, Garzon R, Liu S, Schaaf L, Humphries K, Grever M,

Devine SM, Byrd JC, Marcucci G. Epigenetic targeting via transcriptional inhibition of DNA methyltransferase: a phase I study of bortezomib in combination with 5-azacytidine in adults with relapsed or refractory actue myeloid leukemia (AML). Blood 2009 abstract # 2065

48. Chandler JC, Klisovic KB, Phelps M, Walker A, Garzon R, Yan X, Schaaf L, Schwind S,

Becker H, Liu S, Hickey C, Kefauver C, Mickle J, Devine SM, Grever MR, Byrd JC, Marcucci G, Blum W. Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia. Blood 2009 abstract # 841

49. Chen P, Blum W, Aimiuwu J, Upadhyayula V, Liu Z, Liu S, Pang J, Walker A, Klisovic R,

Garzon R, Grever M, Villalona-Calero M, Byrd JC, Chan K, Marcucci G. Quantification of Intracelluar Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine. Blood 2009 abstract# 3782

50. Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, Curfman J,

Holland KB, Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. Mutations in the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study. Blood 2010 abstract # 98.

51. Attar EC, Donohue KA, Amrein PC, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL,

Voorhees PM, Wang ES, Blum W, Booth A, Stone RM, Moser BK, Larson R. Phase II


Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60-75 Years: Cancer and Leukemia Group B (CALGB) Study 10502. Blood 2010 abstract #331.

52. Khoury HJ, Collins RH, Blum W, Maness L, Stiff P, Kelsey SM, Reddy A, Smith JA,

DiPersio JF. Prolonged Administration of the Telomerase Vaccine GRNVAC1 Is Well Tolerated and Appears to be Associated with Favorable Outcomes in High-Risk Acute Myeloid Leukemia (AML). Blood 2010 abstract #2190.

53. Blum W, Klisovic RB, Garzon R, Walker A, Schwind S, Liu S, Schaaf L, Garr C, Devine

SM, Grever MR, Byrd JC, Marcucci G. Phase I Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML). Blood 2010 abstract #3293.

54. Blum W, Donohue K, Marcucci G, DeAngelo DJ, Uy GL, Powell BL, Stock W, Baer M,

Kolitz JE, Wetzler M, Hoke E, Moser BK, Larson RA. Challenges for Conducting Clinical Trials Evaluating Maintenance Chemotherapy In Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study. Blood 2010 abstract #2176.

55. Lewis C, Heerema NA, Blum W, Whitman J, Hanna J. Culture fibroblasts to determine if

abnormalities are constitutional or part of the patient’s disease state. J Assoc Genetic Technologists. 37(3)” 192 (#41). AGT 2011.

56. Walker A, Metzeler K, Geyer S, Becker H, Schwind S, Whitman S, Curfman J, Wu Y-Z,

Perrotti D, Klisovic R, Garzon R, Blum W, and Marcucci G. Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML) Blood 2011 abstract #944.

57. Mendler J, Maharry K, Radmacher M, Mrózek K, Kohlschmidt J, Nicolet D, Becker H,

Metzeler K, Schwind S, Whitman S, Blum W, Powell B, Kolitz J, Carter T, Wetzler M, MooreJ, Carroll A, Baer M, Larson R, Caligiuri M, Marcucci G, and Bloomfield C. Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures. Blood 2011 abstract #3454.

58. Edwards C, Maharry K, Mrózek K, Schwind S, Paschka P, Nicolet D, Kohlschmidt J, Prior

T, Wu Y-Z, Kolitz J, Blum W, Pettenati M, Dal Cin P, Carroll A, Caligiuri M, Larson R, Marcucci G, and Bloomfield C. Cytogenetic, Molecular and Clinical Features Associated with Rare CBFB-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16) Blood 2011 abstract # 2514

59. Mims AS, Walker AR, Wang H, Huang X, Santhanam R, Hoellerbauer P, Tarighat S, Chan

KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen CS, Blum W, Garzon R, Schwind S, and Marcucci G. AR-42, a Histone Deacetylase Inhibitor, increases microRNA-29b and sensitizes cells to decitabine treatment: a novel epigenetic-targeting approach in Acute Myeloid Leukemia. Presented at AACR March 2012

60. Blum W, Sanford B, Klisovic R, DeAngelo D, Uy G, Powell B, Stock W, Baer M, Kolitz J,

Wetzler M, Hoke E, Bloomfield C, Geyer S, Marcucci G, Stone R, Larson, R. Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance). Blood 2012 abstract #44


61. Wetzler M, Watson D, Stock W, Owzar K, Koval G, Hoke E, McCarty J, Blum W, Powell B, Marcucci G, Bloomfield C, Linker C, Larson R. Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance). Blood 2012 abstract #816

62. Hamadani M, Craig M, Remick S, Gibson L, Petros W, Abraham J, Cumpston A, Bunner P,

Basu S, Tse W, Hennelly C, Vasu S, Klisovic R, Blum W, Jaglowski S, Benson D Jr, Andritsos L, Penza S, Hofmeister C, Geyer S, Devine S, Efebera Y. Immunomodulation of Both Donors and Recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host Disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT). Blood 2012 abstract #1942

63. Jaglowski S, Vasu S, Geyer S, Bingman A, Elder P, Yu J, Blum W, Klisovic R, Penza S,

Efebera Y, Hofmeister C, Benson D, Jr., Muthusamy N, Devine S, Andritsos L, Lozanski G. Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease. Blood 2012 abstract #1949

64. Huang X, Schwind S, Eisfeld A, Yu B, Santhanam R, Hoellerbauer P, Jin Y, Hickey C, Pang

J, Chan K, Perrotti D, Muthusamy N, Byrd J, Blum W, Bloomfield C, Liu S, Garzon R, Lee R, Lee LJ, Marcucci G. Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML). Blood 2012 abstract # 2422.

65. Blum W, Klisovic R, Walker A, Schwind S, Jiang Y, Wang J, Phelps M, Geyer S, Devine S,

Walsh K, Vasu S, Curfman J, Schaaf L, Garr C, Kefauver C, Byrd J, Grever M, Garzon R, Marcucci, G. Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine. Blood 2012 abstract #2619

66. Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Vijayasaradhi UV, Liu Z, Schwind S,

Mims A, Klisovic R, Walker A, Grever M, Villalona-Calero M, Byrd J, Garzon R, Blum W, Chan K, Marcucci, G. Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML). Blood 2012 abstract #3578

67. Klisovic R, Wang H, Walker A, Walsh K, Vasu S, Garzon R, Devine S, Wang J, Garr C,

Norris A, Byrd J, Grever M, Blum W, Chan K, Marcucci G. Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results. Blood 2012 abstract #3616

68. Klisovic R, Wang H, Walker A, Walsh K, Vasu S, Garzon R, Devine S, Wang J, Garr C,

Norris A, Byrd J, Grever M, Blum W, Chan K, Marcucci G. Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results. Blood 2012 abstract #3616

69. Devine SM, Owzar K, Blum W, DeAngelo D, Stone R, Hsu J, Champlin R, Chen Yi-Bin, Vij

R, Slack J, Soiffer R, Larson R, Shea T, Hars V, Bennett E, Spangle S, Giralt S, Carter S, Horowitz M, Linker C, Alyea, E III. A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502. Blood 2012


70. Bernot K, Nemer J, Santhanam R, Gabriel SL, Marcucci G, Zorko N, Whitman S, Yan P,

Frankhouser D, Bundschuh R, Zhang M, Siebenaler R, Ahmed E, McConnell K, Munoz M, Brook D, Dorrance A, Dickerson K, Zhang X, Zhang J, Jarjoura D, Lee R, Caligiuri M, Marcucci G. Targeting the miR29b/Sp1/Dnmt pathway for curative therapy in Mll-PTD/Flt3-ITD acute myeloid leukemia. Poster presentation at AACR 104th Annual Meeting 2013 abstract #3249.

71. Somayeh S. Tarighat, Kiran Mahasenan, Danilo Perrotti, Ramiro Garzon, Michael Caligiuri,

Chenglong Li, Blum W, Guido Marcucci, and Robert A. Baiocchi. Preclinical and pharmacological activities of protein arginine methyltransferase 5(PRMT5) enzyme inhibition in acute myeloid leukemia. Cancer Research 2013 abstract 1128.

72. Guido Marcucci, Susan Geyer, Weiqiang Zhao, Andrew J Caroll, Donna Bucci, Geoffrey L.

Uy, Blum W, Timothy Pardee, Meir Wetzler, Wendy Stock, Jonathan E. Kolitz, Ann-Kathrin Eisfeld, Clara D. Bloomfield, Richard M. Stone, and Richard A. Larson. Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance)

73. Ravi Vij, Vera Hars, Blum W, Tsiporah B. Shore, Aaron P. Rapoport, Thomas C. Shea, Eva

Hoke, Richard M. Stone, Paula Friedman, Kouros Owzar, and Steven M. Devine, MD. CALGB 100801 (Alliance): A Phase II Multi-Center NCI Cooperative Group Study of the Addition of Azacitidine (AZA) to Reduced-Intensity Conditioning (RIC) Allogeneic Transplantation for High Risk Myelodysplasia (MDS) and Older Patients with Acute Myeloid Leukemia (AML): Results of a “test dose” Strategy to Target Busulfan Exposure. 2014

74. Yee KWL, Savona M, Sorensen M, Brown P, Blum WG, DeAngelo DJ, Gutierrez M, Garzon R, Schuh AC, Gabrail NY, Wadleigh M, Lancet JE, Shah BD, Berdeja JG, Wagner-Johnston ND, Flinn I, Rashal T, Kauffman M, Shacham S, Stone RM. A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with relapsed/refractory acute myeloid leukemia (AML). Journal of Clinical Oncology. 2014 May; 32(15s): 7032.

75. Efebera YA, Geyer S, Bingman A, Kitzler R, Elder P, Andritsos LA, Jaglowski SM, Vasu S, Blum W, Klisovic RB, Penza S, Coombes K, Hofmeister CC, Benson D, Devine SM, Lozanski G. Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT). Blood. 2014 Dec; 124(21): 1166.

76. Vij R, Hars V, Blum W, Shore TB, Rapoport AP, Shea TC, Hoke E, Stone RM, Friedman P,

Owzar K, Devine SM. CALGB 100801 (Alliance): A Phase II Multi-Center NCI Cooperative Group Study of the Addition of Azacitidine (AZA) to Reduced-Intensity Conditioning (RIC) Allogeneic Transplantation for High Risk Myelodysplasia (MDS) and Older Patients with Acute Myeloid Leukemia (AML): Results of a “test dose” Strategy to Target Busulfan Exposure. Blood. 2014 Dec; 124(21): 543.

77. Haverkos BM, Cortright K, Andritsos LA, Blum W, Klisovic RB, Vasu S, Goldenberg DM,

Wegener WA, Devine SM, Jaglowski SM. A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies. Blood. 2014 Dec; 124(21): 1168.


78. Vasu S, Bingman A, Geyer S, Elder P, Kitzler R, Bradbury H, Odonnell L, Blum W, Jaglowski SM, Andritsos LA, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Lozanski G, Devine SM. Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation. Blood. 2014 Dec; 124(21): 2494.

79. Marcucci G, Geyer S, Zhao W, Caroll AJ, Bucci D, Uy GL, Blum W, Pardee T, Wetzler M,

Stock W, Kolitz JE, Eisfeld AK, Bloomfield CD, Stone RM, Larson RA. Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance). Blood. 2014 Dec; 124(21): 8.

80. Konopleva M, Pollyea DA, Potluri J, Chyla BJ, Busman T, McKeegan E, Salem A, Zhu M,

Ricker JL, Blum W, DiNardo CD, Dunbar M, Kirby R, Falotico N, Leverson JD, Humerickhouse RA, Mabry M, Stone RM, Kantarjian HM, Letai AG. A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML). Blood. 2014 Dec; 124(21):118.

81. Andritsos LA, Blum W, Klisovic RB, Vasu S, Penza S, Lee J, Marcucci G, Byrd JC, Devine

SM. A Phase I Dose Escalation Study of Lenalidomide Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation. Blood. 2014 Dec; 124(21): 3954.

82. Efebera YA, Geyer S, Bingman A, Elder P, Kitzler R, Coombes K, Hennelly C, Cortright K,

Andritsos LA, Jaglowski SM, Vasu S, Blum W, Klisovic RB, Penza S, Hofmeister CC, Benson DM, Lozanski G, Devine SM. Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT). Blood. 2014 Dec; 124 (21): 3929.

83. Sanford D, Blum WG, Ravandi F, Klisovic RB, Borthakur G, Walker AR, Garcia-Manero G,

Marcucci B, Wierda WG, Whitman SP, Kantarjian HM, Cortes JE. Efficacy and safety of an anti-FLT3 antibody (LY3012218) in patients with relapsed acute myeloid leukemia. Journal of Clinical Oncology. 2015 May; 33(15s): 7059.

84. Khoury HJ, Collins R, Blum WG, Stiff PJ, Lebkowski J, Wirth E, Nishimoto K, DiPersio JF.

Long-term follow-up of patients with acute myelogenous leukemia receiving an autologous telomerase-based dendritic cell vaccine. Journal of Clinical Oncology. 2015 May; 33(15s): 7007.

85. DeAngelo DJ, Stevenson K, Neuberg DS, Silverman LB, Ballen KD, Asch JD, Mourad YA, Paulson K, Seftel MD, Avigan D, Bergeron J, Couban S, Blum W, Storring J, Wadleigh M, Steensma DP, Supko J, Sallan SE, Stone RM. A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial. Blood. 2015 Dec; 126(23): 80.

86. Mitchell S, Orwick S, Cannon M, Goettl VM, LaFollette TD, Baloglu E, Senapedis W, Walker AR, Bhatnagar T, Mims AS, Klisovic RB, Vasu S, Blum W, Lucas DM, Blachly JS, Garzon R, Bloomfield CD, Lapalombella R, Byrd JC. In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease. Blood. 2015 Dec; 126(23): 2471.


87. Sweet KL, Pemmaraju N, Lane AA, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Rowinsky EK, Szarek M, Brooks CL, Disalvatore S, Liu D, Duvic M, Schwartz JD, Konopleva M. Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML). Blood. 2015 Dec; 126(23): 3795.

88. Issa H, Ruppert AS, Elder P, Hofmeister C, Benson DM, Penza S, Andritsos LA, Klisovic RB, Vasu S, Blum W, Jaglowski SM, Devine SM, Efebera YA. Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT). Blood. 2015 Dec; 126(23): 4328.

Reviews or Chapters:

1. Blum W, Picus J. Prostate Cancer. In: Govindan R, ed. The Washington Manual of Oncology.

Philadelphia, Lippincott, Williams, and Wilkins. 2002; 383-393. 2. Blum W, Marcucci G. Targeting epigenetic changes in acute myeloid leukemia. Clin Adv Hematol Oncol. 2005; 3(11):855-65, 882. 3. Blum W and Porcu P. Therapeutic aphaeresis in hyperleukocytosis and hyperviscosity in

hematologic malignancies. Semin Thromb Hemost. 2007; 33(4):350-4.

4. Blum W. Post-remission therapy in acute myeloid leukemia: what should I do now? Haematologica. 2008; 93(6):801-5.

5. Plass C, Oakes C, Blum W, Marcucci G. Epigenetics in acute myeloid leukemia. Semin

Oncol. 2008; 35(4):378-87. 6. Blum W, Marcucci G. New Approaches in acute myeloid leukemia. Best Pract Res Clin

Haematol. 2008; 21(1):29-41. 7. Vasu S, Blum W. Emerging immunotherapies in older adults with acute myeloid leukemia.

Curr Opin Hematol. 2013 Mar;20(2):107-14.

http://www.ncbi.nlm.nih.gov/pubmed/?term=vasu+and+blum

name: william g. blum, m.d. - ohio state university · name: william g. blum, m.d. office address:...

Documents